Join Us!

Get ready for an evening of networking and knowledge sharing with leading experts in the field. Join us to connect with colleagues and hear from a fantastic lineup of speakers from companies including Bayer, VectorY, Sanquin, KlingBio, Enpicom, Carterra and Twist BioPharma.

Registration is mandatory, so be sure to secure your spot!

After a networking lunch at 12:00, our speakers will dive deep into these key topics:

In vitro antibody discovery: Learn about the latest techniques and breakthroughs in finding and selecting antibodies.
Applications of AI/ML in antibody discovery: Explore how artificial intelligence and machine learning are revolutionizing the process.
Antibody production, characterization, and optimization: Gain insights into the essential steps of developing and refining therapeutic antibodies.

We can't wait to see you there!

Enhancing Antibody Discovery through in-silico methods at Bayer

Vanessa Verissimo, Senior Scientist

Bayer | Therapeutic Antibodies

In the field of antibody drug discovery, it is essential to accelerate the identification of therapeutic molecules while maintaining accuracy. This presentation delves into the shift from conventional high-throughput screening to in silico-assisted approaches, leveraging next-generation sequencing and machine learning to broaden antibody diversity and reduce reliance on wet-lab experiments. Bayer's advanced biologics platform enables the swift generation and purification of thousands of molecules, allowing for comprehensive multidimensional characterization. This innovative strategy fosters a quicker, more cost-effective early-stage drug discovery process.

Precision targeted therapies for neurodegenerative diseases

Susanne Snoek, Senior Scientist Vectorized Antibodies

VectorY Therapeutics | Research

Based in Amsterdam and founded in 2020, VectorY is dedicated to developing innovative vectorized antibody therapies for neurodegenerative diseases such as ALS, Huntington’s, and Parkinson’s.
By combining advanced antibody engineering with adeno-associated virus (AAV)-based delivery, our proprietary platform enables long-lasting, targeted treatments to the central nervous system.
This approach overcomes current therapeutic limitations, offering potential for disease modification and improved patient outcomes.

Validation of Structural-Based Machine Learning Designed In Vitro Libraries

Hoa Giang

Twist BioPharma | BioPharma Product Leader

At Twist Biopharma Solutions, we continue to develop and integrate new technologies to enable our antibody discovery partners to identify and optimize lead therapeutic candidates with speed, precision and accuracy. By synergizing Twist DNA synthesis with its library assembly technology and structural-based machine learning partnership, target specific antibody libraries were generated. Through successive rounds of panning, several highly potent and selective lead antibodies against C5aR were discovered. These antibodies exhibited functionally antagonistic effects on C5aR1-mediated signaling in cell-based assays. In our second library, binders that could distinguish between two highly homologous undisclosed targets (~97%) are desired. Initial data suggests that these binders are present. This work demonstrates how the combination of specific DNA synthesis coupled with informed design can be paired to successfully prosecute challenging targets for novel therapeutic discovery.

The dual face of IgG4 antibodies

Prof Theo (T.) Rispens, Principal Investigator

Sanquin | Antibody Structure & Function | Dept. Molecular Cell Bio. and Immuno. UMC

IgG4 antibodies are unique to humans. These antibodies are only a minor fraction of total IgG, but specific antibody responses can be dominated by this response, including autoantibody responses, and antidrug antibodies. Due to its special, non-inflammatory properties, it is often considered a 'tolerogenic' antibody, counteracting e.g. allergic IgE responses, but it may also cause autoimmune disease and concerns for immune evasion have been raised upon repeated vaccinations. Here we will discuss the special properties of IgG4 and the consequences for the associated (patho)physiological effects.

Immortalized patients’ derived B cell libraries for the interrogation and unbiased discovery of novel therapeutic targets and antibodies in oncology and beyond.

Casper Marsman, B Cell Platform Lead Department

Kling Biotherapeutics | B Cell Platform Development

Kling Biotherapeutics presents their B cell immortalization platform that transforms antibody discovery by capturing the complete diversity of patient-derived B cell repertoires. Their proprietary technology overcomes the limited lifespan of primary B cells, enabling comprehensive functional screening and immediate antibody production from culture supernatants.
The Kling B cell Tumor Libraries (TuLibs) approach captures B cells from all tissues and immunoglobulin isotypes, providing significant advantages over traditional BCR sequencing methods. Unlike labor-intensive recombinant antibody production, this platform allows direct functional screening while maintaining indefinite expansion capabilities. The immortalized B cells retain capacity for somatic hypermutation, enabling in vitro affinity maturation against specific targets. The Kling Bio technology has already enabled the discovery and development of two AML-specific antibodies targeting previously unknown tumor antigens, and identified cross-variant neutralizing antibodies against SARS-CoV-2.
Kling’s platform represents a paradigm shift in therapeutic antibody discovery, offering unprecedented access to natural human immune repertoires for developing targeted cancer and infectious disease therapies.

Antibody Discovery Meetup

Wednesday, October 29, 2025 - From 12:00 to 16:30 CET